United Therapeutics Corporation $UTHR Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 14.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,113 shares of the biotechnology company’s stock after selling 3,847 shares during the quarter. SG Americas Securities LLC’s holdings in United Therapeutics were worth $13,706,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Clearstead Advisors LLC raised its holdings in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares during the last quarter. Independent Advisor Alliance boosted its stake in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares during the last quarter. Florida Financial Advisors LLC increased its position in United Therapeutics by 5.4% during the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares in the last quarter. NDVR Inc. increased its position in United Therapeutics by 5.1% during the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30 shares in the last quarter. Finally, Principal Securities Inc. raised its stake in United Therapeutics by 4.7% in the 4th quarter. Principal Securities Inc. now owns 686 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on UTHR shares. Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $541.55, for a total transaction of $4,494,865.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,462,896.60. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 8,750 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $538.15, for a total value of $4,708,812.50. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,158,119.40. This represents a 31.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 643,218 shares of company stock worth $363,705,304 in the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $542.66 on Friday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The company’s 50 day simple moving average is $561.23 and its 200 day simple moving average is $525.58. The stock has a market capitalization of $23.04 billion, a PE ratio of 20.03, a P/E/G ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the company posted $6.63 EPS. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.49 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.